HOME >> BIOLOGY >> NEWS
Weill Cornell team identifies potential new cancer drug target

NEW YORK (June 20, 2007) -- Research led by scientists at Weill Cornell Medical College has uncovered two new potential points of vulnerability on a key cancer-promoting protein, called XIAP. Drugs that target either of these activities could help push cancer cells back into a more regular programmed cell death and thereby reduce or eliminate tumors.

These findings were published in the June 8 issue of Molecular Cell by Dr. Hao Wu, a professor in the Department of Biochemistry of Weill Cornell, and her team.

Experts know that cancers spread in two separate ways -- by the uncontrolled proliferation of cells, and by their refusal to undergo normal, healthy, programmed cell death, or "apoptosis."

In many cancers, dysfunction in a biochemical cascade called the NF-kappa B pathway causes tumor cells to sidestep apoptosis and become dangerously immortal.

"So, drug development aimed at short-circuiting NF-kappa B has become very hot in the past few years," Dr. Wu says.

Her team focused on a particular protein involved in the NF-kappa B pathway called the "X-linked inhibitor of apoptosis" (XIAP). Scientists had already discovered that XIAP thwarts the apoptotic impulse by putting the brakes on key enzymes called caspases. XIAP is also known to be highly active in cancer cells, but it is found in relatively low levels in healthy cells. How XIAP inhibits caspases is known, but how XIAP induces NF-kappa B activation is entirely unclear.

"We wondered if we could find out how XIAP induces the NF-kappa B pathway," explains lead researcher Dr. Miao Lu, a postdoctoral fellow of biochemistry at Weill Cornell.

In their experiments, the researchers used a variety of cutting-edge techniques, including X-ray crystallography, to track changes in the structure and activity of XIAP and the molecules it interacts with in cells.

"We discovered that XIAP interacts with the NF-kappa B cycle in two distinct wa
'"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
21-Jun-2007


Page: 1 2

Related biology news :

1. Weill Cornell pharmacologist receives prestigious NIH MERIT Award
2. Stem cell research at Weill Cornell, The Rockefeller University, and Sloan-Kettering
3. Weill Cornell team develops fast-acting anthrax vaccine
4. Cornell scientists link E. coli bacteria to Crohns disease
5. Methodist, University of Houston, Cornell combine biomedical imaging expertise
6. Cornell lab confirms deadly fish virus spreading to new species
7. NSF awards $3.3 million grant to Cornell to bolster the percentage of women faculty members
8. Cornell researchers find serious fish virus in Northeast for first time
9. Cornell finds natural selection in humans
10. Northeast Sun Grant Institute at Cornell spurs green revolution
11. Cornell graduate student named 2005 AIBS Emerging Public Policy Leader

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... June 13, 2019 , ... KICVentures announced today its plans ... Orthopedic and Pain Management-Driven ASC Conference in Chicago on Thursday, June 13th at 6:30 ... Dr. Chicago, IL in the 3rd floor Ticino Hospitality room in space #74T. , ...
(Date:6/11/2019)... ... 10, 2019 , ... Improved Pharma LLC announces the publication of “Predictive and ... The article was published online on April 29th, 2019. The authors are Stephen ... Chen of Purdue University. , The article is the most recent addition to a ...
(Date:6/6/2019)... ... June 05, 2019 , ... Ziegler, a ... advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent acquisition by PathGroup. ... that provides services to more than one dozen hospitals and surgery centers in ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... and ROANOKE, Va. (PRWEB) , ... June 11, ... ... optimized for microlearning engagement, and Carilion Clinic, a national leader in opioid treatment, ... latest in virtual care. , Mytonomy recently deployed its virtual care ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... applications from the USPTO providing proprietary interest to our methodology, processes, and ... DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep ...
(Date:5/21/2019)... ... May 21, 2019 , ... DuPont ... officially opened the inaugural Africa Brewing Conference dedicated to sharing brewing knowledge, strengthening ... The event, which is supported through a partnership with “Ethiopia Invest”, will run ...
(Date:5/8/2019)... ... ... Atlas is on the large side for a Quarter Horse. He and his owner ... When loping around a corner in late 2017, Atlas tripped and partially tore his right ... to walk. Fortunately Atlas’ owner, Kelly, sought the opinion of her veterinarian, Dr. Colter ...
Breaking Biology Technology:
Cached News: